Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia - Concepedia

Concepedia

Publication | Open Access

Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia

DOI Full Paper Access

86

Citations

38

References

2017

Year

Sandrine Degryse, Charles E. de Bock, Sofie Demeyer, Inge Govaerts, Simon Bornschein, Delphine Verbeke, Kris Jacobs, Steve Binos, David A. Skerrett‐Byrne, Heather C. Murray,

References

	Year	Citations

Page 1